PLZF-RARα is the second most
frequent variant acute promyelocytic
leukemia (APL) fusion protein that ranks after PML-RARα in APL.
However, PLZF-RARα is resistant to current front line APL treatments
including all transretinoic acid (ATRA), arsenic trioxide (ATO), and
chemotherapy (i.e., Idarubicin). Herein, we for the first time report
that phenylarsine oxide (PAO) could effectively induce PLZF-RARα
variant fusion protein degradation through ubiquitin proteasome degradation
pathway by apoptosis, which indicates that PAO might be a potential
candidate for the treatment of PLZF-RARα variant APL. Given
that, this study highlights the potential benefit of arsenic-organometallic
compound PAO in APL treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.